

# Kyowa Kirin Co., Ltd.

## Appendix to the Consolidated Financial Summary (IFRS) Fiscal 2025

(January 1, 2025 - December 31, 2025)

- These materials were made as a supplement to the Kessan Tanshin (Consolidated Financial Summary, IFRS), disclosed at the Tokyo Stock Exchange on February 9, 2026 for Fiscal 2025, from January 1, 2025 to December 31, 2025.
- This document is an English translation of the Japanese-language original.
- The statements, including earnings forecasts, contained in these materials are based on the information currently available to the Company and on certain assumptions deemed to be reasonable by management. As such, they do not constitute guarantees by the Company of future performance. Actual results may differ materially from these projections for a wide variety of reasons.
- Figures presented in these materials have been rounded to the nearest tenth
- Figures inside parenthesis presented in these materials indicate negative values.
- Change amount in these materials presents change amount compared to the same period of the previous fiscal year.

---

| Index  | Page |
|--|------|
| I. Consolidated Financial Results  |      |
| 1. Trends in consolidated profit   | 1    |
| 2. Trends in consolidated profit<br>(-Based on the newly defined Core Operating Profit)    | 2    |
| 3. Revenue by regional control function  | 3    |
| 4. Capital expenditures and intangible assets investment,<br>depreciation and amortization | 3    |
| 5. Number of employees by regional control function  | 3    |
| II. Consolidated Statement of Cash Flows   | 3    |
| III. Status of Main Products   |      |
| 1. Revenue by Products   | 4    |
| 2. Revenue by Location   | 5    |
| 3. Collaboration Products  | 6    |
| IV. R&D Pipeline   | 7    |

---

The average exchange rates for each period were as follows:

Unit: Yen

|     | FY 2024 results |           |           |           | FY 2025 results |           |           |           | FY2026<br>forecasts |
|-----|-----------------|-----------|-----------|-----------|-----------------|-----------|-----------|-----------|---------------------|
|     | Jan - Mar       | Jan - Jun | Jan - Sep | Jan - Dec | Jan - Mar       | Jan - Jun | Jan - Sep | Jan - Dec |                     |
| USD | 147             | 151       | 151       | 151       | 154             | 150       | 149       | 150       | 150                 |
| GBP | 187             | 191       | 193       | 193       | 193             | 193       | 195       | 197       | 205                 |
| EUR | 160             | 163       | 164       | 164       | 161             | 162       | 165       | 168       | 180                 |

Contact  
Kyowa Kirin Co., Ltd.  
Corporate Communications Department  
Tel +81 3 5205 7206

## I. Consolidated Financial Results

## 1. Trends in consolidated profit

|   | FY 2024 results |           |           |           |           |           |           |         | FY 2025 results |                |                            |                | Unit: Billions of yen |  |
|---|-----------------|-----------|-----------|-----------|-----------|-----------|-----------|---------|-----------------|----------------|----------------------------|----------------|-----------------------|--|
|   | Jan - Mar       | Jan - Jun | Jan - Sep | Jan - Dec | Jan - Mar | Jan - Jun | Jan - Sep | Jan-Dec | Change amount   | Rate of change | Jan - Dec latest forecasts | % of forecasts |                       |  |
| Revenue   | 105.6           | 233.0     | 362.8     | 495.6     | 104.7     | 230.7     | 349.5     | 496.8   | 1.3             | 0%             | 478.0                      | 104%           |                       |  |
| ★ CAGR (compared to FY 2020)  | -               | -         | -         | 11.7%     | -         | -         | -         | 9.3%    | -               | -              | 8.5%                       | -              |                       |  |
| Cost of sales   | (25.6)          | (59.5)    | (94.0)    | (132.6)   | (24.6)    | (61.9)    | (90.1)    | (127.9) | 4.7             | (4)%           | (126.0)                    | 102%           |                       |  |
| Gross profit  | 80.0            | 173.5     | 268.8     | 362.9     | 80.1      | 168.8     | 259.4     | 368.9   | 5.9             | 2%             | 352.0                      | 105%           |                       |  |
| Gross profit to revenue ratio   | 75.8%           | 74.5%     | 74.1%     | 73.2%     | 76.5%     | 73.2%     | 74.2%     | 74.2%   | -               | -              | 73.6%                      | -              |                       |  |
| Selling, general and administrative expenses                            | (40.2)          | (83.2)    | (123.6)   | (167.5)   | (42.0)    | (82.8)    | (121.5)   | (165.4) | 2.1             | (1)%           | (166.0)                    | 100%           |                       |  |
| Research and development expenses                                       | (23.3)          | (49.2)    | (74.3)    | (103.5)   | (28.6)    | (52.5)    | (76.8)    | (101.2) | 2.4             | (2)%           | (107.0)                    | 95%            |                       |  |
| ★ R&D expense ratio   | 22.1%           | 21.1%     | 20.5%     | 20.9%     | 27.3%     | 22.8%     | 22.0%     | 20.4%   | -               | -              | 22.4%                      | -              | Target of 18-20%      |  |
| Share of profit (loss) of investments accounted for using equity method | 0.9             | 3.1       | 3.5       | 3.5       | (0.9)     | 1.5       | 1.0       | 0.8     | (2.8)           | (78)%          | 1.0                        | 79%            |                       |  |
| Core Operating Profit <sup>1</sup>                                      | 17.4            | 44.1      | 74.4      | 95.4      | 8.6       | 35.0      | 62.0      | 103.1   | 7.7             | 8%             | 80.0                       | 129%           |                       |  |
| ★ Core operating profit ratio   | 16.5%           | 18.9%     | 20.5%     | 19.3%     | 8.2%      | 15.2%     | 17.7%     | 20.7%   | -               | -              | 16.7%                      | -              | 25% or higher         |  |
| Other income  | 2.6             | 4.4       | 13.3      | 13.1      | 0.4       | 0.6       | 0.7       | 1.1     | (12.0)          | (92)%          |                            |                |                       |  |
| Other expenses  | (2.8)           | (4.7)     | (16.9)    | (19.3)    | (1.6)     | (12.9)    | (14.7)    | (18.0)  | 1.3             | (7)%           |                            |                |                       |  |
| Finance income (costs)  | 0.8             | 2.6       | 0.8       | (5.8)     | 0.4       | (0.7)     | (0.1)     | 1.1     | 6.8             | -              |                            |                |                       |  |
| Profit before tax   | 18.1            | 46.5      | 71.6      | 83.5      | 7.9       | 22.0      | 47.9      | 87.2    | 3.8             | 5%             | 74.0                       | 118%           |                       |  |
| Income tax expense  | (3.5)           | (8.7)     | (15.7)    | (23.6)    | (1.7)     | (5.7)     | (15.3)    | (20.2)  | 3.4             | (14)%          | (17.0)                     | 119%           |                       |  |
| Ratio of income tax burden  | 19.2%           | 18.8%     | 21.9%     | 28.3%     | 21.5%     | 25.7%     | 32.0%     | 23.1%   | -               | -              | 23.0%                      | -              |                       |  |
| Profit  | 14.6            | 37.8      | 55.9      | 59.9      | 6.2       | 16.3      | 32.6      | 67.0    | 7.2             | 12%            | 57.0                       | 118%           |                       |  |
| Profit to revenue ratio   | 13.9%           | 16.2%     | 15.4%     | 12.1%     | 5.9%      | 7.1%      | 9.3%      | 13.5%   | -               | -              | 11.9%                      | -              |                       |  |
| EPS (¥/share)   | 27.26           | 70.76     | 105.20    | 113.06    | 11.78     | 31.18     | 62.28     | 128.07  | 15.01           | -              | 108.91                     |                |                       |  |
| Core EPS (¥/share) <sup>2</sup>   | 27.46           | 71.16     | 110.52    | 121.44    | 13.57     | 48.63     | 80.46     | 152.90  | 31.46           | -              | 119.23                     |                |                       |  |
| Annual dividend (¥/share)   |                 |           |           | 58.00     |           |           |           | 62.00   | 4.00            |                | 60.00                      |                |                       |  |
| ★ Dividend payout ratio (%) <sup>3</sup>                                |                 |           |           | 47.8      |           |           |           | 40.5    | (7.2)           |                | 50.3                       |                | Target of 40%         |  |
| ★ ROE (%)   |                 |           |           | 7.1       |           |           |           | 7.7     | 0.6             |                | 6.6                        |                | 10% or higher         |  |

<sup>1</sup> Core operating profit = Gross profit - Selling, general and administrative expenses - Research and development expenses + Share of profit (loss) of investments accounted for using equity method.

<sup>2</sup> Core EPS is calculated as an indicator showing recurring profitability by dividing core profit (determined by subtracting "other income," "other expenses" and the related "income tax expense" from "profit") by the average number of shares during the period.

<sup>3</sup> Dividend payout ratio is shown based on core EPS.

|   | FY 2024 results |           |           |           |           |           |           |           | FY 2025 results |                |  |  | Unit: Billions of yen |  |
|---|-----------------|-----------|-----------|-----------|-----------|-----------|-----------|-----------|-----------------|----------------|--|--|-----------------------|--|
|   | Jan - Mar       | Apr - Jun | Jul - Sep | Oct - Dec | Jan - Mar | Apr - Jun | Jul - Sep | Oct - Dec | Change amount   | Rate of change |  |  |                       |  |
| Revenue   | 105.6           | 127.4     | 129.8     | 132.8     | 104.7     | 125.9     | 118.8     | 147.4     | 14.6            | 11%            |  |  |                       |  |
| Cost of sales   | (25.6)          | (33.9)    | (34.5)    | (38.6)    | (24.6)    | (37.3)    | (28.2)    | (37.9)    | 0.7             | (2)%           |  |  |                       |  |
| Gross profit  | 80.0            | 93.5      | 95.3      | 94.2      | 80.1      | 88.7      | 90.6      | 109.5     | 15.3            | 16%            |  |  |                       |  |
| Gross profit to revenue ratio   | 75.8%           | 73.4%     | 73.4%     | 70.9%     | 76.5%     | 70.4%     | 76.3%     | 74.3%     | -               | -              |  |  |                       |  |
| Selling, general and administrative expenses                            | (40.2)          | (43.1)    | (40.4)    | (43.9)    | (42.0)    | (40.8)    | (38.7)    | (43.9)    | 0.0             | (0)%           |  |  |                       |  |
| Research and development expenses                                       | (23.3)          | (25.9)    | (25.0)    | (29.3)    | (28.6)    | (23.9)    | (24.3)    | (24.3)    | 4.9             | (17)%          |  |  |                       |  |
| ★ R&D expense ratio   | 22.1%           | 20.4%     | 19.3%     | 22.0%     | 27.3%     | 19.0%     | 20.5%     | 16.5%     | -               | -              |  |  |                       |  |
| Share of profit (loss) of investments accounted for using equity method | 0.9             | 2.2       | 0.4       | 0.0       | (0.9)     | 2.5       | (0.6)     | (0.2)     | (0.2)           | -              |  |  |                       |  |
| Core operating profit   | 17.4            | 26.7      | 30.3      | 21.0      | 8.6       | 26.4      | 27.0      | 41.1      | 20.1            | 96%            |  |  |                       |  |
| ★ Core operating profit ratio   | 16.5%           | 21.0%     | 23.3%     | 15.8%     | 8.2%      | 21.0%     | 22.7%     | 27.9%     | -               | -              |  |  |                       |  |
| Other income  | 2.6             | 1.8       | 8.9       | (0.2)     | 0.4       | 0.2       | 0.2       | 0.3       | 0.5             | -              |  |  |                       |  |
| Other expenses  | (2.8)           | (1.9)     | (12.2)    | (2.4)     | (1.6)     | (11.3)    | (1.9)     | (3.3)     | (0.8)           | 35%            |  |  |                       |  |
| Finance income (costs)  | 0.8             | 1.8       | (1.9)     | (6.5)     | 0.4       | (1.2)     | 0.7       | 1.1       | 7.7             | -              |  |  |                       |  |
| Profit before tax   | 18.1            | 28.4      | 25.1      | 11.9      | 7.9       | 14.1      | 25.9      | 39.3      | 27.4            | 231%           |  |  |                       |  |
| Income tax expense  | (3.5)           | (5.3)     | (6.9)     | (7.9)     | (1.7)     | (4.0)     | (9.7)     | (4.9)     | 3.1             | (39)%          |  |  |                       |  |
| Profit  | 14.6            | 23.1      | 18.1      | 4.0       | 6.2       | 10.2      | 16.3      | 34.4      | 30.5            | 768%           |  |  |                       |  |
| Profit to revenue ratio   | 13.9%           | 18.2%     | 14.0%     | 3.0%      | 5.9%      | 8.1%      | 13.7%     | 23.4%     | -               | -              |  |  |                       |  |

## I. Consolidated Financial Results

### 2. Trends in consolidated profit (Based on the newly defined Core Operating Profit) <Accumulative - New Core Base>

|   | FY 2024 results |           |           |           | FY 2025 results |           |           |           |               | FY 2026 forecasts |           | FY 2028 forecasts                |                 |
|---|-----------------|-----------|-----------|-----------|-----------------|-----------|-----------|-----------|---------------|-------------------|-----------|----------------------------------|-----------------|
|   | Jan - Mar       | Jan - Jun | Jan - Sep | Jan - Dec | Jan - Mar       | Jan - Jun | Jan - Sep | Jan - Dec | Change amount | Rate of change    | Jan - Dec | Rate of change                   |                 |
| Revenue   | 105.6           | 233.0     | 362.8     | 495.6     | 104.7           | 230.7     | 349.5     | 496.8     | 1.3           | 0%                | 520.0     | 5%                               |                 |
| Cost of sales   | (25.6)          | (59.5)    | (94.0)    | (132.6)   | (24.6)          | (61.9)    | (90.1)    | (127.9)   | 4.7           | (4)%              | (129.0)   | 1%                               |                 |
| Gross profit  | 80.0            | 173.5     | 268.8     | 362.9     | 80.1            | 168.8     | 259.4     | 368.9     | 5.9           | 2%                | 391.0     | 6%                               |                 |
| <i>Gross profit to revenue ratio</i>                                    | 75.8%           | 74.5%     | 74.1%     | 73.2%     | 76.5%           | 73.2%     | 74.2%     | 74.2%     | -             | -                 | 75.2%     | -                                |                 |
| Selling, general and administrative expenses <sup>2</sup>               | (38.8)          | (79.7)    | (117.7)   | (160.0)   | (40.4)          | (79.5)    | (116.5)   | (157.9)   | 2.1           | (1)%              | (169.0)   | 7%                               |                 |
| Research and development expenses                                       | (23.3)          | (49.2)    | (74.3)    | (103.5)   | (28.6)          | (52.5)    | (76.8)    | (101.2)   | 2.4           | (2)%              | (122.0)   | 21%                              |                 |
| ★ <i>R&amp;D expense ratio</i>  | 22.1%           | 21.1%     | 20.5%     | 20.9%     | 27.3%           | 22.8%     | 22.0%     | 20.4%     | -             | -                 | 23.5%     | -                                |                 |
| Core operating profit   | 17.9            | 44.5      | 76.8      | 99.4      | 11.2            | 36.8      | 66.1      | 109.8     | 10.4          | 10%               | 100.0     | (9)%                             |                 |
| ★ <i>Core operating profit ratio</i>                                    | 16.9%           | 19.1%     | 21.2%     | 20.1%     | 10.7%           | 16.0%     | 18.9%     | 22.1%     | -             | -                 | 19.2%     | -                                | Early 20% range |
| Amortization (intangible assets) <sup>3</sup>                           | (1.4)           | (3.5)     | (6.0)     | (7.6)     | (1.7)           | (3.4)     | (5.1)     | (7.6)     | 0.0           | (0)%              | (11.0)    | 45%                              |                 |
| Share of profit (loss) of investments accounted for using equity method | 0.9             | 3.1       | 3.5       | 3.5       | (0.9)           | 1.5       | 1.0       | 0.8       | (2.8)         | (78)%             | (2.0)     | -                                |                 |
| Other income  | 2.6             | 4.4       | 13.3      | 13.1      | 0.4             | 0.6       | 0.7       | 1.1       | (12.0)        | (92)%             |           |                                  |                 |
| Other expenses  | (2.8)           | (4.7)     | (16.9)    | (19.3)    | (1.6)           | (12.9)    | (14.7)    | (18.0)    | 1.3           | (7)%              |           |                                  |                 |
| Finance income (costs)  | 0.8             | 2.6       | 0.8       | (5.8)     | 0.4             | (0.7)     | (0.1)     | 1.1       | 6.8           | -                 |           |                                  |                 |
| Profit before tax   | 18.1            | 46.5      | 71.6      | 83.5      | 7.9             | 22.0      | 47.9      | 87.2      | 3.8           | 5%                | 95.0      | 9%                               |                 |
| Income tax expense  | (3.5)           | (8.7)     | (15.7)    | (23.6)    | (1.7)           | (5.7)     | (15.3)    | (20.2)    | 3.4           | (14)%             | (20.0)    | (1)%                             |                 |
| Ratio of income tax burden  | 19.2%           | 18.8%     | 21.9%     | 28.3%     | 21.5%           | 25.7%     | 32.0%     | 23.1%     | -             | -                 | -         | -                                |                 |
| Profit  | 14.6            | 37.8      | 55.9      | 59.9      | 6.2             | 16.3      | 32.6      | 67.0      | 7.2           | 12%               | 75.0      | 12%                              |                 |
| Profit to revenue ratio   | 13.9%           | 16.2%     | 15.4%     | 12.1%     | 5.9%            | 7.1%      | 9.3%      | 13.5%     | -             | -                 | 14.4%     | -                                |                 |
| ROE(%)  |                 |           |           |           | 7.1             |           |           |           | 7.7           | 0.6               | 8.2       |                                  |                 |
| ★ ROE(%) ≈ Three-year average   |                 |           |           |           | 8.2             |           |           |           | 8.3           | 0.1               | 7.7       | 7% or higher                     |                 |
| ★ DOE(%) <sup>4</sup>   |                 |           |           |           | 3.6             |           |           |           | 3.8           | 0.2               | 4.1       | Progressive payout of 4% or more |                 |

### <Accumulative - New Core Base>

|                                 | FY 2024 results |           |           |           | FY 2025 results |           |           |           |               | FY 2026 forecasts |           | Unit: Billions of yen |  |
|---------------------------------|-----------------|-----------|-----------|-----------|-----------------|-----------|-----------|-----------|---------------|-------------------|-----------|-----------------------|--|
|                                 | Jan - Mar       | Jan - Jun | Jan - Sep | Jan - Dec | Jan - Mar       | Jan - Jun | Jan - Sep | Jan - Dec | Change amount | Rate of change    | Jan - Dec | Rate of change        |  |
| Core operating profit           | 17.9            | 44.5      | 76.8      | 99.4      | 11.2            | 36.8      | 66.1      | 109.8     | 10.4          | 10%               | 100.0     | (9)%                  |  |
| Income tax expense              | (3.4)           | (8.4)     | (16.8)    | (28.1)    | (2.4)           | (9.5)     | (21.1)    | (25.4)    | 2.7           | (10)%             | (20.0)    | (21)%                 |  |
| Ratio of income tax burden      | 19.2%           | 18.8%     | 21.9%     | 28.3%     | 21.5%           | 25.7%     | 32.0%     | 23.1%     | -             | -                 | -         | -                     |  |
| Core Profit <sup>1</sup>        | 14.5            | 36.2      | 60.0      | 71.3      | 8.8             | 27.4      | 44.9      | 84.4      | 13.1          | 18%               | 80.0      | (5)%                  |  |
| Core EPS (¥/share) <sup>5</sup> | 26.93           | 67.74     | 112.93    | 134.72    | 16.83           | 52.25     | 85.85     | 161.28    | 26.56         | -                 | 152.82    | -                     |  |

<sup>1</sup> We have adopted core indicators as performance metrics that offer better comparability with global pharma, reflecting group's sustainable profitability.

The new core operating profit is calculated by deducting selling, general and administrative expenses (excl. amortization of intangible assets) and research and development expenses from gross profit, and further excluding non-recurring items determined by the company.

The new core profit for the period is calculated by deducting income tax expense attributable to the relevant core operating profit from the new core operating profit.

<sup>2</sup> Selling, general and administrative expenses do not include amortization of intangible assets.

<sup>3</sup> Amortization of marketing rights is presented as amortization of intangible assets.

<sup>4</sup> DOE is calculated by dividing the dividend amount by the beginning-of-period capital.

<sup>5</sup> The new core EPS is calculated by dividing the new core profit for the period by the weighted average number of shares outstanding during the period.

<sup>6</sup> For the actual results in 2024 and 2025 and the forecast for 2026, the Company did not exclude any items as non-recurring gains or losses, as determined by the Company.

### <Quarterly - New Core Base>

|   | FY 2024 results |           |           |           | FY 2025 results |           |           |           |               | FY 2026 forecasts |           | Unit: Billions of yen |  |
|---|-----------------|-----------|-----------|-----------|-----------------|-----------|-----------|-----------|---------------|-------------------|-----------|-----------------------|--|
|   | Jan - Mar       | Apr - Jun | Jul - Sep | Oct - Dec | Jan - Mar       | Apr - Jun | Jul - Sep | Oct - Dec | Change amount | Rate of change    | Jan - Dec | Rate of change        |  |
| Revenue   | 105.6           | 127.4     | 129.8     | 132.8     | 104.7           | 125.9     | 118.8     | 147.4     | 14.6          | 11%               |           |                       |  |
| Cost of sales   | (25.6)          | (33.9)    | (34.5)    | (38.6)    | (24.6)          | (37.3)    | (28.2)    | (37.9)    | 0.7           | (2)%              |           |                       |  |
| Gross profit  | 80.0            | 93.5      | 95.3      | 94.2      | 80.1            | 88.7      | 90.6      | 109.5     | 15.3          | 16%               |           |                       |  |
| <i>Gross profit to revenue ratio</i>                                    | 75.8%           | 73.4%     | 73.4%     | 70.9%     | 76.5%           | 70.4%     | 76.3%     | 74.3%     | -             | -                 |           |                       |  |
| Selling, general and administrative expenses                            | (38.8)          | (40.9)    | (37.9)    | (42.3)    | (40.4)          | (39.1)    | (37.0)    | (41.4)    | 0.9           | (2)%              |           |                       |  |
| Research and development expenses                                       | (23.3)          | (25.9)    | (25.0)    | (29.3)    | (28.6)          | (23.9)    | (24.3)    | (24.3)    | 4.9           | (17)%             |           |                       |  |
| ★ <i>R&amp;D expense ratio</i>  | 22.1%           | 20.4%     | 19.3%     | 22.0%     | 27.3%           | 19.0%     | 20.5%     | 16.5%     | -             | -                 |           |                       |  |
| Core operating profit   | 17.9            | 26.7      | 32.3      | 22.6      | 11.2            | 25.6      | 29.2      | 43.8      | 21.2          | 94%               |           |                       |  |
| ★ <i>Core operating profit ratio</i>                                    | 16.9%           | 20.9%     | 24.9%     | 17.0%     | 10.7%           | 20.3%     | 24.6%     | 29.7%     | -             | -                 |           |                       |  |
| Amortization (intangible assets)  | (1.4)           | (2.1)     | (2.4)     | (1.6)     | (1.7)           | (1.7)     | (1.7)     | (2.5)     | (0.9)         | 54%               |           |                       |  |
| Share of profit (loss) of investments accounted for using equity method | 0.9             | 2.2       | 0.4       | 0.0       | (0.9)           | 2.5       | (0.6)     | (0.2)     | (0.2)         | -                 |           |                       |  |
| Other income  | 2.6             | 1.8       | 8.9       | (0.2)     | 0.4             | 0.2       | 0.2       | 0.3       | 0.5           | -                 |           |                       |  |
| Other expenses  | (2.8)           | (1.9)     | (12.2)    | (2.4)     | (1.6)           | (11.3)    | (1.9)     | (3.3)     | (0.8)         | 35%               |           |                       |  |
| Finance income (costs)  | 0.8             | 1.8       | (1.9)     | (6.5)     | 0.4             | (1.2)     | 0.7       | 1.1       | 7.7           | -                 |           |                       |  |
| Profit before tax   | 18.1            | 28.4      | 25.1      | 11.9      | 7.9             | 14.1      | 25.9      | 39.3      | 27.4          | 231%              |           |                       |  |
| Income tax expense  | (3.5)           | (5.3)     | (6.9)     | (7.9)     | (1.7)           | (4.0)     | (9.7)     | (4.9)     | 3.1           | -                 |           |                       |  |
| Profit  | 14.6            | 23.1      | 18.1      | 4.0       | 6.2             | 10.2      | 16.3      | 34.4      | 30.5          | 768%              |           |                       |  |
| Profit to revenue ratio   | 13.9%           | 18.2%     | 14.0%     | 3.0%      | 5.9%            | 8.1%      | 13.7%     | 23.4%     | -             | -                 |           |                       |  |

### <Quarterly - New Core Base>

|                       | FY 2024 results |           |           |           | FY 2025 results |           |           |           |               | FY 2026 forecasts |           | Unit: Billions of yen |  |
|-----------------------|-----------------|-----------|-----------|-----------|-----------------|-----------|-----------|-----------|---------------|-------------------|-----------|-----------------------|--|
|                       | Jan - Mar       | Apr - Jun | Jul - Sep | Oct - Dec | Jan - Mar       | Apr - Jun | Jul - Sep | Oct - Dec | Change amount | Rate of change    | Jan - Dec | Rate of change        |  |
| Core operating profit | 17.9            | 26.7      | 32.3      | 22.6      | 11.2            | 25.6      | 29.2      | 43.8      | 21.2          | 94%               |           |                       |  |
| Income tax expense    | (3.5)           | (4.9)     | (6.9)     | (7.9)     | (1.7)           | (4.0)     | (9.7)     | (4.9)     | 3.1           | -                 |           |                       |  |
| Core profit           | 14.5            | 21.7      | 23.8      | 11.3      | 8.8             | 18.5      | 17.6      | 39.5      | 28.2          | 248%              |           |                       |  |

## 3. Revenue by regional control function

&lt;Accumulative&gt;

|                                 | FY 2024 results |           |           |           | FY 2025 results |           |           |           | FY 2026 forecasts |           |
|---------------------------------|-----------------|-----------|-----------|-----------|-----------------|-----------|-----------|-----------|-------------------|-----------|
|                                 | Jan - Mar       | Jan - Jun | Jan - Sep | Jan - Dec | Jan - Mar       | Jan - Jun | Jan - Sep | Jan - Dec | Change amount     | Jan - Dec |
| Japan                           | 31.6            | 65.3      | 98.0      | 134.7     | 27.2            | 58.4      | 89.7      | 122.5     | (12.1)            | 111.5     |
| North America                   | 32.3            | 79.9      | 120.1     | 174.4     | 35.5            | 88.4      | 129.9     | 192.5     | 18.1              | 211.0     |
| EMEA                            | 16.7            | 36.9      | 65.7      | 84.9      | 19.7            | 37.0      | 62.4      | 83.7      | (1.3)             | 78.5      |
| Others                          | 25.0            | 50.9      | 78.9      | 101.5     | 22.3            | 46.9      | 67.5      | 98.1      | (3.4)             | 119.0     |
| Total consolidated revenue      | 105.6           | 233.0     | 362.8     | 495.6     | 104.7           | 230.7     | 349.5     | 496.8     | 1.3               | 520.0     |
| Japan (location of customer)    | 34.3            | 68.6      | 100.9     | 141.2     | 28.3            | 63.1      | 96.0      | 128.8     | (12.4)            | 120.0     |
| Overseas (location of customer) | 71.3            | 164.4     | 261.9     | 354.4     | 76.4            | 167.6     | 253.4     | 368.0     | 13.6              | 400.0     |
| Overseas ratio                  | 68%             | 71%       | 72%       | 72%       | 73%             | 73%       | 73%       | 74%       | -                 | 77%       |

\* Revenue by regional control function is classified based on consolidated revenue from products of regional control functions in the One Kyowa Kirin (OKK) matrix global management structure, which combines a regional organization, a functional organization, and a product organization (product franchises).

\* EMEA consists of Europe, the Middle East, Africa, etc.

\* Others consists of revenue from technology out-licensing, revenue from APAC, hematopoietic stem cell gene therapy (revenue from Orchard Therapeutics), original equipment manufacturing, etc.

\* Revenue that was classified under "APAC" in 2024, will be included in "Others" starting from 2025 due to the business reorganization in the APAC region.

## &lt;Quarterly&gt;

|                            | FY 2024 results |           |           |           |           |           |           |           | FY 2025 results |  |
|----------------------------|-----------------|-----------|-----------|-----------|-----------|-----------|-----------|-----------|-----------------|--|
|                            | Jan - Mar       | Apr - Jun | Jul - Sep | Oct - Dec | Jan - Mar | Apr - Jun | Jul - Sep | Oct - Dec | Change amount   |  |
| Japan                      | 31.6            | 33.7      | 32.8      | 36.6      | 27.2      | 31.2      | 31.3      | 32.8      | (3.8)           |  |
| North America              | 32.3            | 47.6      | 40.2      | 54.3      | 35.5      | 52.8      | 41.5      | 62.6      | 8.3             |  |
| EMEA                       | 16.7            | 20.1      | 28.8      | 19.2      | 19.7      | 17.3      | 25.3      | 21.3      | 2.1             |  |
| Others                     | 25.0            | 26.0      | 28.0      | 22.6      | 22.3      | 24.5      | 20.6      | 30.6      | 8.0             |  |
| Total consolidated revenue | 105.6           | 127.4     | 129.8     | 132.8     | 104.7     | 125.9     | 118.8     | 147.4     | 14.6            |  |

## 4. Capital expenditures and intangible assets investment, depreciation and amortization

|   | FY 2024 results |           |           |           | FY 2025 results |           |           |           | FY 2026 forecasts |  |
|---|-----------------|-----------|-----------|-----------|-----------------|-----------|-----------|-----------|-------------------|--|
|   | Jan - Mar       | Jan - Jun | Jan - Sep | Jan - Dec | Jan - Mar       | Jan - Jun | Jan - Sep | Jan - Dec | Jan - Dec         |  |
| Capital expenditures (property, plant and equipment) <sup>1</sup> | 4.9             | 12.3      | 19.0      | 29.5      | 8.2             | 14.9      | 22.9      | 35.0      | 33.9              |  |
| Intangible assets investment                                      | 17.7            | 21.9      | 25.5      | 79.3      | 1.3             | 9.9       | 21.3      | 48.1      | 18.3              |  |
| Total   | 22.5            | 34.2      | 44.6      | 108.7     | 9.4             | 24.9      | 44.2      | 83.1      | 52.2              |  |
| Depreciation (property, plant and equipment)                      | 3.7             | 7.4       | 11.0      | 14.8      | 3.8             | 7.6       | 11.7      | 15.8      | 16.8              |  |
| Amortization (intangible assets)                                  | 2.0             | 4.7       | 7.8       | 10.0      | 2.3             | 4.7       | 7.1       | 10.4      | 15.0              |  |
| Of which, sales right <sup>2</sup>                                | 1.4             | 3.5       | 6.0       | 7.6       | 1.7             | 3.4       | 5.1       | 7.6       | 11.1              |  |
| Total   | 5.6             | 12.1      | 18.8      | 24.8      | 6.1             | 12.3      | 18.8      | 26.1      | 31.7              |  |

\*1 Acquisitions of right-of-use assets are not included.

\*2 From 2026 onward, amortization of intangible assets will be presented as a separate line item in the consolidated statement of profit or loss.

## 5. Number of employees by regional control function

|               | FY 2024 results |              |              |              | FY 2025 results |              |              |              | As of Dec 31 |
|---------------|-----------------|--------------|--------------|--------------|-----------------|--------------|--------------|--------------|--------------|
|               | As of Mar 31    | As of Jun 30 | As of Sep 30 | As of Dec 31 | As of Mar 31    | As of Jun 30 | As of Sep 30 | As of Dec 31 |              |
| Japan         | 4,090           | 4,103        | 4,093        | 4,020        | 3,898           | 3,890        | 3,882        | 3,508        | (512)        |
| North America | 648             | 664          | 664          | 668          | 709             | 678          | 699          | 706          | 38           |
| EMEA          | 543             | 548          | 553          | 547          | 538             | 540          | 544          | 551          | 4            |
| Others        | 873             | 866          | 877          | 434          | 375             | 381          | 387          | 397          | (37)         |
| Total         | 6,154           | 6,181        | 6,186        | 5,669        | 5,520           | 5,489        | 5,512        | 5,161        | (508)        |

\* Others consists of number of employees of APAC subsidiaries, Orchard Therapeutics, etc.

\* Number of employees that were classified under "APAC" in 2024, will be included in "Others" starting from 2025 due to the business reorganization in the APAC region.

## II. Consolidated Statement of Cash Flows

|  | FY 2024 results |           |           |           | FY 2025 results |           |           |           | As of Dec 31 |
|--|-----------------|-----------|-----------|-----------|-----------------|-----------|-----------|-----------|--------------|
|  | Jan - Mar       | Jan - Jun | Jan - Sep | Jan - Dec | Jan - Mar       | Jan - Jun | Jan - Sep | Jan - Dec |              |
| Cash flows from operating activities                         | 19.2            | 46.9      | 69.6      | 67.9      | 7.4             | 39.8      | 69.6      | 100.0     | 32.1         |
| Cash flows from investing activities                         | (50.3)          | (80.5)    | (95.8)    | (142.4)   | (21.5)          | (34.7)    | (41.6)    | (92.6)    | 49.8         |
| Cash flows from financing activities                         | (41.3)          | (63.2)    | (83.7)    | (84.7)    | (16.5)          | (17.2)    | (33.6)    | (36.9)    | 47.8         |
| Effect of exchange rate changes on cash and cash equivalents | 2.5             | 4.9       | 3.1       | 0.8       | 0.3             | 2.0       | 1.2       | 3.5       | 2.7          |
| Net increase (decrease) in cash and cash equivalents         | (70.0)          | (91.9)    | (106.8)   | (158.4)   | (30.3)          | (10.1)    | (4.5)     | (25.9)    | 132.5        |
| Cash and cash equivalents at beginning of period             | 403.1           | 403.1     | 403.1     | 403.1     | 244.7           | 244.7     | 244.7     | 244.7     | (158.4)      |
| Cash and cash equivalents at end of period                   | 333.1           | 311.1     | 296.3     | 244.7     | 214.4           | 234.6     | 240.2     | 218.8     | (25.9)       |

### III. Status of Main Products

#### 1. Revenue by Products

&lt;Accumulative&gt;

Unit: Billions of yen

|   | FY 2024 results |              |              |              | FY 2025 results |              |              |              |               |                            | FY 2026 forecasts |              |                |
|---|-----------------|--------------|--------------|--------------|-----------------|--------------|--------------|--------------|---------------|----------------------------|-------------------|--------------|----------------|
|   | Jan - Mar       | Jan - Jun    | Jan - Sep    | Jan - Dec    | Jan - Mar       | Jan - Jun    | Jan - Sep    | Jan - Dec    | Change amount | Jan - Dec latest forecasts | % of forecasts    | Jan - Dec    | Rate of change |
| Products <sup>*1</sup>                          | 93.4            | 208.7        | 327.9        | 446.8        | 91.8            | 205.2        | 310.1        | 438.4        | (8.4)         | 425.7                      | 103%              | 445.1        | 2%             |
| <i>Crysvita</i>                                 | 37.8            | 90.9         | 134.9        | 196.6        | 42.4            | 99.8         | 146.7        | 216.4        | 19.8          | 210.2                      | 103%              | 235.4        | 9%             |
| <i>Poteligeo</i>                                | 8.6             | 19.1         | 29.1         | 39.9         | 9.8             | 21.6         | 33.7         | 45.7         | 5.8           | 45.4                       | 101%              | 54.6         | 20%            |
| <i>Libmeldy/Lenmeldy</i>                        | 1.1             | 1.4          | 2.2          | 3.3          | 2.1             | 4.4          | 4.4          | 6.4          | 3.2           | 6.9                        | 94%               | 10.0         | 56%            |
| <i>Nourianz</i>                                 | 1.6             | 3.5          | 6.2          | 8.8          | 2.0             | 4.6          | 6.9          | 9.5          | 0.7           | 8.2                        | 116%              | 7.4          | (22)%          |
| <i>PHOZEVEL</i>                                 | 0.6             | 1.7          | 2.9          | 4.7          | 1.5             | 3.7          | 5.9          | 8.2          | 3.6           | 8.9                        | 92%               | 11.6         | 41%            |
| <i>Duvroq</i>                                   | 2.5             | 5.7          | 8.9          | 12.7         | 3.0             | 6.9          | 10.9         | 15.5         | 2.8           | 15.5                       | 100%              | 16.2         | 5%             |
| <i>Nesp</i>                                     | 0.7             | 1.4          | 2.0          | 2.6          | 0.5             | 0.9          | 1.1          | 1.4          | (1.3)         | 2.0                        | 71%               | 0.8          | (41)%          |
| <i>Darbepoetin Alfa Injection Syringe [KKF]</i> | 2.8             | 5.6          | 8.5          | 11.6         | 2.3             | 4.9          | 7.6          | 10.4         | (1.1)         | 9.6                        | 109%              | 9.2          | (12)%          |
| <i>G-Lasta</i>                                  | 5.8             | 10.5         | 15.3         | 20.5         | 4.3             | 9.1          | 13.7         | 18.2         | (2.4)         | 17.0                       | 107%              | 16.2         | (11)%          |
| <i>Romiplate</i>                                | 3.0             | 6.5          | 9.9          | 13.9         | 3.4             | 7.3          | 11.5         | 15.9         | 2.0           | 14.6                       | 109%              | 11.4         | (28)%          |
| <i>Orkedia</i>                                  | 2.2             | 4.9          | 7.5          | 10.4         | 2.4             | 5.4          | 8.2          | 11.3         | 0.9           | 10.7                       | 106%              | 11.6         | 3%             |
| <i>Rituximab BS [KHK]</i>                       | 1.9             | 3.8          | 5.7          | 7.8          | 1.5             | 3.2          | 5.0          | 6.9          | (1.0)         | 6.0                        | 114%              | 7.9          | 16%            |
| <i>Nouriast</i>                                 | 1.5             | 3.4          | 5.1          | 6.9          | 1.4             | 3.1          | 4.6          | 6.3          | (0.6)         | 6.5                        | 97%               | 5.1          | (19)%          |
| <i>HARUROPI</i>                                 | 1.0             | 2.2          | 3.3          | 4.6          | 1.0             | 2.1          | 3.3          | 4.5          | (0.0)         | 4.8                        | 95%               | 4.0          | (12)%          |
| <i>Dovobet</i> <sup>*2</sup>                    | 1.8             | 3.9          | 5.8          | 7.9          | -               | -            | -            | -            | (7.9)         | -                          | -                 | -            | -              |
| Technology out-licensing <sup>*3</sup>          | 12.1            | 24.3         | 34.9         | 48.8         | 13.0            | 25.5         | 39.4         | 58.4         | 9.7           | 52.3                       | 112%              | 74.9         | 28%            |
| Benralizumab royalty <sup>*4</sup>              | 6.4             | 14.4         | 21.6         | 31.4         | 7.4             | 15.7         | 25.4         | 38.1         | 6.7           |                            |                   |              |                |
| <b>Total</b>                                    | <b>105.6</b>    | <b>233.0</b> | <b>362.8</b> | <b>495.6</b> | <b>104.7</b>    | <b>230.7</b> | <b>349.5</b> | <b>496.8</b> | <b>1.3</b>    | <b>478.0</b>               |                   | <b>520.0</b> |                |

&lt;Quarterly&gt;

Unit: Billions of yen

|   | FY 2024 results |              |              |              | FY 2025 results |              |              |              | Change amount |
|---|-----------------|--------------|--------------|--------------|-----------------|--------------|--------------|--------------|---------------|
|   | Jan - Mar       | Apr - Jun    | Jul - Sep    | Oct - Dec    | Jan - Mar       | Apr - Jun    | Jul - Sep    | Oct - Dec    |               |
| Products <sup>*1</sup>                          | 93.4            | 115.3        | 119.2        | 118.9        | 91.8            | 113.4        | 104.9        | 128.3        | 9.4           |
| <i>Crysvita</i>                                 | 37.8            | 53.0         | 44.0         | 61.7         | 42.4            | 57.3         | 46.9         | 69.7         | 8.0           |
| <i>Poteligeo</i>                                | 8.6             | 10.4         | 10.0         | 10.8         | 9.8             | 11.8         | 12.1         | 12.0         | 1.2           |
| <i>Libmeldy/Lenmeldy</i>                        | 1.1             | 0.3          | 0.7          | 1.1          | 2.1             | 2.3          | (0.0)        | 2.0          | 0.9           |
| <i>Nourianz</i>                                 | 1.6             | 2.0          | 2.6          | 2.6          | 2.0             | 2.6          | 2.3          | 2.6          | (0.0)         |
| <i>PHOZEVEL</i>                                 | 0.6             | 1.1          | 1.2          | 1.8          | 1.5             | 2.1          | 2.2          | 2.3          | 0.6           |
| <i>Duvroq</i>                                   | 2.5             | 3.2          | 3.3          | 3.8          | 3.0             | 3.8          | 4.1          | 4.6          | 0.8           |
| <i>Nesp</i>                                     | 0.7             | 0.7          | 0.6          | 0.7          | 0.5             | 0.4          | 0.3          | 0.3          | (0.4)         |
| <i>Darbepoetin Alfa Injection Syringe [KKF]</i> | 2.8             | 2.8          | 2.9          | 3.1          | 2.3             | 2.6          | 2.7          | 2.8          | (0.3)         |
| <i>G-Lasta</i>                                  | 5.8             | 4.7          | 4.8          | 5.2          | 4.3             | 4.8          | 4.6          | 4.5          | (0.7)         |
| <i>Romiplate</i>                                | 3.0             | 3.4          | 3.5          | 4.0          | 3.4             | 3.9          | 4.2          | 4.4          | 0.4           |
| <i>Orkedia</i>                                  | 2.2             | 2.7          | 2.5          | 3.0          | 2.4             | 2.9          | 2.9          | 3.1          | 0.1           |
| <i>Rituximab BS [KHK]</i>                       | 1.9             | 1.9          | 1.9          | 2.1          | 1.5             | 1.7          | 1.8          | 1.8          | (0.3)         |
| <i>Nouriast</i>                                 | 1.5             | 1.9          | 1.7          | 1.9          | 1.4             | 1.7          | 1.6          | 1.7          | (0.2)         |
| <i>HARUROPI</i>                                 | 1.0             | 1.2          | 1.1          | 1.3          | 1.0             | 1.2          | 1.1          | 1.3          | (0.0)         |
| <i>Dovobet</i> <sup>*2</sup>                    | 1.8             | 2.1          | 1.8          | 2.1          | -               | -            | -            | -            | (2.1)         |
| Technology out-licensing <sup>*3</sup>          | 12.1            | 12.2         | 10.7         | 13.8         | 13.0            | 12.5         | 13.9         | 19.1         | 5.3           |
| Benralizumab royalty <sup>*4</sup>              | 6.4             | 8.0          | 7.1          | 9.9          | 7.4             | 8.3          | 9.7          | 12.7         | 2.9           |
| <b>Total</b>                                    | <b>105.6</b>    | <b>127.4</b> | <b>129.8</b> | <b>132.8</b> | <b>104.7</b>    | <b>125.9</b> | <b>118.8</b> | <b>147.4</b> | <b>14.6</b>   |

\*1 For revenue for Japan, the figures shown are those before the deduction of discounts and other items, and for revenue for overseas, the figures shown are those after the deduction of discounts and other items and include the impact of exchange rates.

\*2 Due to the termination of the distribution and co-promotion agreement with LEO Pharma K.K. for Dovobet, sales by the Company ended on December 31, 2024.

\*3 Revenue listed as "Technology out-licensing" represents the upfront income, milestone revenue and running royalty income that are obtained based on licensing agreements recognizing the granting to third parties the rights for development, manufacturing and sales of the Group's pipeline compounds or the use of technology, etc.

\*4 Benralizumab royalty only refers to the royalty on sales of Fasenra by AstraZeneca (including the Company's own estimates).

### III. Status of Main Products

#### 2. Revenue by Location

<Accumulative>

| Product name      | FY 2024 results   |               |               |           |           | FY 2025 results |           |           |               |                            |                | FY 2026 forecasts |                |
|-------------------|-------------------|---------------|---------------|-----------|-----------|-----------------|-----------|-----------|---------------|----------------------------|----------------|-------------------|----------------|
|                   | Jan - Mar         | Jan - Jun     | Jan - Sep     | Jan - Dec | Jan - Mar | Jan - Jun       | Jan - Sep | Jan - Dec | Change amount | Jan - Dec latest forecasts | % of forecasts | Jan - Dec         | Rate of change |
| Crysvita          | 37.8              | 90.9          | 134.9         | 196.6     | 42.4      | 99.8            | 146.7     | 216.4     | 19.8          | 210.2                      | 103%           | 235.4             | 9%             |
|                   | Japan             | 2.5           | 5.4           | 8.2       | 11.7      | 2.8             | 6.1       | 9.7       | 1.9           | 13.1                       | 104%           | 14.7              | 8%             |
|                   | North America     | 22.8          | 58.7          | 87.2      | 130.0     | 24.1            | 64.0      | 92.0      | 141.8         | 11.7                       | 197.1          | 220.7             | 9%             |
|                   | [Millions of USD] | 155           | 388           | 575       | 860       | 157             | 430       | 620       | 946           | 86                         |                |                   |                |
|                   | EMEA              | 11.9          | 25.4          | 37.1      | 51.5      | 14.8            | 28.0      | 42.4      | 57.5          | 6.0                        |                |                   |                |
|                   | [Millions of GBP] | 64            | 133           | 193       | 267       | 77              | 145       | 219       | 293           | 26                         |                |                   |                |
|                   | Others            | 0.6           | 1.3           | 2.3       | 3.3       | 0.8             | 1.7       | 2.6       | 3.5           | 0.3                        |                |                   |                |
| Poteligeo         | 8.6               | * <u>19.1</u> | * <u>29.1</u> | 39.9      | 9.8       | 21.6            | 33.7      | 45.7      | 5.8           | 45.4                       | 101%           | 54.6              | 20%            |
|                   | Japan             | 0.4           | 1.0           | 1.4       | 1.8       | 0.3             | 0.7       | 1.2       | 1.6           | (0.2)                      | 1.9            | 86%               | 1.4            |
|                   | North America     | 6.3           | 14.1          | 21.6      | 29.7      | 6.9             | 16.0      | 25.1      | 33.9          | 4.2                        | 34.1           | 100%              | 40.9           |
|                   | [Millions of USD] | 43            | 93            | 143       | 197       | 45              | 107       | 169       | 227           | 30                         | 235            | 97%               | 273            |
|                   | EMEA              | 1.9           | 3.9           | 6.0       | 8.2       | 2.6             | 4.9       | 7.3       | 10.0          | 1.8                        | 9.2            | 109%              | 12.0           |
|                   | [Millions of GBP] | 10            | 21            | 31        | 43        | 13              | 25        | 38        | 51            | 8                          | 48             | 105%              | 59             |
|                   | Others            | 0.0           | 0.1           | 0.1       | 0.1       | 0.0             | 0.1       | 0.1       | 0.2           | 0.0                        | 0.3            | 52%               | 0.2            |
| Libmeldy/Lenmeldy | 1.1               | 1.4           | 2.2           | 3.3       | 2.1       | 4.4             | 4.4       | 6.4       | 3.1           | 6.9                        | 93%            | 10.0              | 56%            |
|                   | US                | -             | -             | -         | -         | 1.1             | 1.6       | 1.6       | 2.9           | 2.9                        |                |                   | 4.5            |
|                   | EMEA              | 1.1           | 1.4           | 2.2       | 3.3       | 1.0             | 2.8       | 2.8       | 3.5           | 0.2                        |                |                   | 5.5            |

\* The underlined portion indicates that the amount has been changed from the amount [19.0] and [29.0] presented in "Appendix to the Consolidated Financial Summary (IFRS) Fiscal 2025 Second Quarter".

<Quarterly>

Unit: Billions of yen

| Product name      | FY 2024 results   |           |           |           |           | FY 2025 results |           |           |               |       | Change amount |  |
|-------------------|-------------------|-----------|-----------|-----------|-----------|-----------------|-----------|-----------|---------------|-------|---------------|--|
|                   | Jan - Mar         | Apr - Jun | Jul - Sep | Oct - Dec | Jan - Mar | Apr - Jun       | Jul - Sep | Oct - Dec | Change amount |       |               |  |
| Crysvita          | 37.8              | 53.0      | 44.0      | 61.7      | 42.4      | 57.3            | 46.9      | 69.7      | 8.0           |       |               |  |
|                   | Japan             | 2.5       | 2.9       | 2.8       | 3.6       | 2.8             | 3.3       | 3.6       | 3.9           |       |               |  |
|                   | North America     | 22.8      | 35.9      | 28.6      | 42.8      | 24.1            | 39.9      | 28.0      | 49.8          |       |               |  |
|                   | [Millions of USD] | 155       | 233       | 187       | 285       | 157             | 273       | 191       | 325           |       |               |  |
|                   | EMEA              | 11.9      | 13.5      | 11.7      | 14.4      | 14.8            | 13.2      | 14.4      | 15.1          |       |               |  |
|                   | [Millions of GBP] | 64        | 70        | 59        | 74        | 77              | 68        | 74        | 74            |       |               |  |
|                   | Others            | 0.6       | 0.7       | 0.9       | 1.0       | 0.8             | 1.0       | 0.9       | 0.9           | (0.1) |               |  |
| Poteligeo         | 8.6               | 10.4      | 10.0      | 10.9      | 9.8       | 11.8            | 12.1      | 12.0      | 1.1           |       |               |  |
|                   | Japan             | 0.4       | 0.5       | 0.4       | 0.5       | 0.3             | 0.4       | 0.5       | 0.5           |       |               |  |
|                   | North America     | 6.3       | 7.8       | 7.5       | 8.1       | 6.9             | 9.1       | 9.1       | 8.8           |       |               |  |
|                   | [Millions of USD] | 43        | 51        | 49        | 54        | 45              | 62        | 62        | 58            |       |               |  |
|                   | EMEA              | 1.9       | 2.0       | 2.0       | 2.3       | 2.6             | 2.3       | 2.5       | 2.7           |       |               |  |
|                   | [Millions of GBP] | 10        | 10        | 10        | 12        | 13              | 12        | 13        | 13            |       |               |  |
|                   | Others            | 0.0       | 0.1       | 0.0       | 0.0       | 0.0             | 0.0       | 0.0       | 0.1           | 0.0   |               |  |
| Libmeldy/Lenmeldy | 1.1               | 0.3       | 0.7       | 1.1       | 2.1       | 2.3             | (0.0)     | 2.0       | 0.9           |       |               |  |
|                   | US                | -         | -         | -         | -         | 1.1             | 0.5       | (0.0)     | 1.3           |       |               |  |
|                   | EMEA              | 1.1       | 0.3       | 0.7       | 1.1       | 1.0             | 1.8       | (0.0)     | 0.7           |       |               |  |

\* The revenue, generated in various currencies inside each corporate region, is converted and aggregated in USD for North America and in GBP for EMEA.

\* Revenue that was classified under "APAC" in 2024, will be included in "Others" starting from 2025 due to the business reorganization in the APAC region.

### III. Status of Main Products

#### 3. Collaboration Product

<Accumulative>

| Product name                                 | FY2025 results<br>Unit: Billions of yen |           |           |           |
|--|---|-----------|-----------|-----------|
|  | Jan - Mar                               | Jan - Jun | Jan - Sep | Jan - Dec |
| KOMZIFTI <sup>1</sup>                        |   |           |           |           |
| Revenue                                      | -                                       | -         | -         | 0.3       |
| [Millions of USD]                            | -                                       | -         | -         | 2         |
| Profit/Loss                                  | (1.3)                                   | (3.1)     | (5.5)     | (8.2)     |
| [Millions of USD]                            | (8)                                     | (20)      | (37)      | (55)      |
| Our group (50% share)                        |   |           |           |           |
| Revenue                                      | -                                       | -         | -         | -         |
| Selling, general and administrative expenses | (0.6)                                   | (1.5)     | (2.8)     | (4.1)     |
| Core operating profit <sup>2</sup>           | (0.6)                                   | (1.5)     | (2.8)     | (4.1)     |
| Amortization (intangible assets)             | -                                       | -         | -         | (0.7)     |
| Profit before tax                            | (0.6)                                   | (1.5)     | (2.8)     | (4.8)     |

<Quarterly>

| Product name                                 | FY2025 results<br>Unit: Billions of yen |           |           |           |
|--|---|-----------|-----------|-----------|
|  | Jan - Mar                               | Apr - Jun | Jul - Sep | Oct - Dec |
| KOMZIFTI <sup>1</sup>                        |   |           |           |           |
| Revenue                                      | -                                       | -         | -         | 0.3       |
| [Millions of USD]                            | -                                       | -         | -         | 2         |
| Profit/Loss                                  | (1.3)                                   | (1.8)     | (2.5)     | (2.7)     |
| [Millions of USD]                            | (8)                                     | (12)      | (17)      | (18)      |
| Our group (50% share)                        |   |           |           |           |
| Revenue                                      | -                                       | -         | -         | -         |
| Selling, general and administrative expenses | (0.6)                                   | (0.9)     | (1.2)     | (1.3)     |
| Core operating profit <sup>2</sup>           | (0.6)                                   | (0.9)     | (1.2)     | (1.3)     |
| Amortization (intangible assets)             | -                                       | -         | -         | (0.7)     |
| Profit before tax                            | (0.6)                                   | (0.9)     | (1.2)     | (2.1)     |

\*1 For KOMZIFTI, under the strategic collaboration agreement with Kura Oncology, profits in the United States will be shared on a 50:50 basis.

The Group records the net profit or loss after profit sharing as revenue when it is positive and as selling, general and administrative expenses when it is negative; in the current consolidated fiscal year, the net result was negative and therefore has been recorded under selling, general and administrative expenses.

\*2 This is core operating profit based on the new definition. For details, please refer to "I. Consolidated Financial Results: 2. Trends in consolidated profit (Based on the newly defined Core Operating Profit)"

## IV. R&amp;D pipeline

Legend:  small molecule  antibody  HSC-GT  Updated since Dec. 31, 2024  Updated since Sep. 30, 2025

As of Dec 31, 2025

| Code Name<br>Generic Name<br>Formulation  | Mechanism of Action                        | Indication                                       | Stage   |   |   | [In-House or Licensed]<br>Remarks   |
|---|--|--|---|---|---|---|
|   |  |  | PhI   | PhII  | PhIII   |   |
|  KK8123<br>Injection                           | Anti-FGF23 Fully Human Antibody            | X-linked Hypophosphatemia                        |    |   |   | [In-House]<br>Clinical study is being conducted in NA and EU as a global product  |
|  KK8398<br>infigratinib<br>Oral                | FGFR3 Inhibitor                            | Achondroplasia                                   |    |    |    | [QED Therapeutics]<br>Clinical study is being conducted in JP   |
|   |  | Hypochondroplasia                                |   |   |   | Preparation underway for Ph III clinical trial in JP  |
|  ziftomenib<br>Oral                            | Menin Inhibitor                            | Acute Lymphoblastic Leukemia (ALL) (Monotherapy) |    |   |   | [Kura Oncology]<br>Clinical study is being conducted in NA and EU as a global product<br>KMT2A-rearranged ALL<br>KOMET-001  |
|   |  | Acute Myeloid Leukemia (AML) (Monotherapy)       |    |   |   | Clinical study is being conducted in NA and EU as a global product<br>Non-NPM1-mutant AML/Non-KMT2A-rearranged AML<br>KOMET-001   |
|   |  | Acute Myeloid Leukemia (AML) (Combination)       |   |   |   | Adult Relapsed or Refractory AML with a NPM1 Mutation<br>Preparation underway for Ph II clinical trial in JP  |
|   |  |  |    |   |   | Clinical study is being conducted in NA as a global product<br>NPM1-mutant AML/KMT2A-rearranged AML<br>Combinations with venetoclax + azacitidine, and cytarabine + daunorubicin<br>KOMET-007   |
|   |  |  |   |    |    | Clinical study is being conducted in NA as a global product<br>FLT3/NPM1 co-mutated AML<br>Combinations with cytarabine + daunorubicin, and quizartinib<br>KOMET-007  |
|   |  |  |  |   |   | Clinical study is being conducted in NA and EU as a global product<br>NPM1-mutant AML/KMT2A-rearranged AML<br>Combinations with gilteritinib, FLAG-IDA, LDAC<br>KOMET-008   |
|   |  |  |   |  |  |    |
|  KK2845                                      | Anti-TIM-3 ADC                             | Acute Myeloid Leukemia (AML)                     |  |   |   | [In-House]<br>Antibody-Drug Conjugate<br>Clinical study is being conducted in JP as a global product  |
|  OTL-203                                     | Hematopoietic Stem Cell (HSC) Gene Therapy | MPS-IH (Hurler Syndrome)                         |  |  |  | [In-House]<br>Rare Pediatric Disease (RPD) and Fast Track designations (FDA)<br>Priority Medicines (PRIME) designation (EMA)<br>Area of clinical study: NA and EU   |
|  OTL-201                                     | Hematopoietic Stem Cell (HSC) Gene Therapy | MPS-III A (Sanfilippo Syndrome type A)           |  |  | Ph I /<br>Ph II   | [In-House]<br>Rare Pediatric Disease (RPD) designation (FDA)<br>Preparation underway for registrational study (equivalent to PhIII study)   |
|  KHK4083/AMG 451<br>rocacitinib<br>Injection | Anti-OX40 Antibody                         | Moderate to Severe Atopic Dermatitis             |  |  |  | [In-House]<br>POTELLIGENT<br>Human monoclonal antibody production technology<br>Collaboration agreement with Amgen for the development of rocacitinib in all the countries except for Japan<br>Clinical study is being conducted in JP, NA, EU, UK, Middle East, Asia, Oceania, and other regions as a global product |
|   |  | Prurigo Nodularis                                |  |  |  | Clinical study is being conducted in JP, NA, EU, Asia, and Oceania as a global product  |
|   |  | Moderate to Severe Asthma                        |  |  |   | Clinical study is being conducted in JP, NA, EU, Asia, and Oceania as a global product  |
|  KHK4951<br>tivozanib<br>Ophthalmic          | VEGF Receptor Tyrosine Kinase Inhibitor    | Diabetic Macular Edema                           |  |  |   | [In-House]<br>Clinical study is being conducted in JP, NA, Asia, and Oceania as a global product  |
|   |  | Neovascular Age-Related Macular Degeneration     |  |  |   | Clinical study is being conducted in JP, NA, Asia, and Oceania as a global product  |
|  KK2260<br>Injection                         | EGFR-TfR1 Bispecific Antibody              | Advanced or Metastatic Solid Tumors              |  |   |   | [In-House]<br>REGULGENT<br>Fully human antibody production technology<br>Clinical study is being conducted in JP, and a clinical study is prepared under way for PhI in NA as a global product  |

## IV. R&amp;D pipeline

| Code Name<br>Generic Name  | Mechanism of Action                        | Indication   | Stage   |      |       | [In-House or Licensed]<br>Remarks   |
|--|--|--|---|------|-------|---|
|  |  |  | PhI   | PhII | PhIII |   |
|  KK2269<br>Injection                | EpCAM-CD40Bispecific Antibody              | Advanced or Metastatic Solid Tumors                        |  |      |       | [In-House]<br>REGULGENT<br>Fully human antibody production technology<br>Clinical study is being conducted in JP and NA as a global product   |
|  KK4277<br>Injection                | Anti-PTPRS Humanized Antibody              | Systemic Lupus Erythematosus/Cutaneous Lupus Erythematosus |  |      |       | [SBI Biotech]<br>POTELLIGENT<br>Clinical study is being conducted in JP and Asia  |
|  KK3910<br>Injection                |  | Essential Hypertension                                     |  |      |       | [In-House]<br>Clinical study is being conducted in JP as a global product   |
|  OTL-200<br>atidarsagene autotemcel | Hematopoietic Stem Cell (HSC) Gene Therapy | Early-onset Metachromatic Leukodystrophy (MLD)             |   |      |       | [In-House]<br>Orphan Regenerative Medicine Product Designation in JP<br>Preparation underway for clinical trial in JP<br>Product Name in US: Lemmeldy<br>Product Name in Europe: Libmeldy |

※ For detailed information on ziftomenib's development status, please refer to Kura Oncology's website. <https://kuraoncology.com/>

Note: Our main progress from December 31, 2025 is as follows

• On January 30, 2026, Kyowa Kirin announced that termination of the current KHK4083/AMG 451 (rocatinlimab) collaboration with Amgen and Kyowa Kirin will regain control of KHK4083/AMG 451 development and commercialization program.

## Major Applications and Approvals

| Code Name, Generic Name, Product Name        | Indication  | Application/Under Review | Countries/Regions Received Approval in 2025 |
|--|---|--------------------------|---|
| ziftomenib(Product name in the US: KOMZIFTI) | Adult Relapsed or Refractory (R/R) Acute Myeloid Leukemia (AML) with a Nucleophosmin1 (NPM1) Mutation | –                        | US  |